Fiallo M, Laigle A, Garnier-Suillerot A, Amirand C, Ballini J P, Chinsky L, Duquesne M, Jolles B, Sureau F, Turpin P Y
Laboratoire de Physique et Chimie Biomoléculaires, Université Pierre et Marie Curie, Paris, France.
Biochim Biophys Acta. 1993 Jun 30;1177(3):236-44. doi: 10.1016/0167-4889(93)90119-a.
The interaction of iron-anthracycline complexes with tumor cells has been studied using microspectrofluorometry. The anthracyclines used were adriamycin, 4'-O-tetrahydropyranyladriamycin and daunorubicin. In every case, a 1:3 Fe(III)-anthracycline complex is formed. The three daunorubicin molecules that bind to one Fe(III) are not chemically modified through complexation with iron. In the case of the Fe(III)-adriamycin and Fe(III)-4'-O-tetrahydropyranyladriamycin complexes, about one of the three anthracycline molecules is chemically modified, yielding a highly lipophilic derivative, the 7,8-dehydro-9,10-desacetyladriamycin. The others molecules remain unchanged, i.e., highly hydrophilic in the case of adriamycin. These two species have a different fluorescent spectrum and can be identified inside the cell, using microspectrofluorometry. In the case of the Fe(III)-adriamycin complex, the lipophilic derivative is more rapidly internalized in the cell than the hydrophilic one. Diffusion into the plasmic membrane is the limiting step for the uptake of anthracycline by cells; this means that the plasmic membrane speeds up the dissociation of the Fe(III)-anthracycline complex.
已使用显微分光荧光测定法研究了铁-蒽环类药物复合物与肿瘤细胞的相互作用。所使用的蒽环类药物为阿霉素、4'-O-四氢吡喃基阿霉素和柔红霉素。在每种情况下,都会形成1:3的Fe(III)-蒽环类药物复合物。与一个Fe(III)结合的三个柔红霉素分子不会因与铁络合而发生化学修饰。在Fe(III)-阿霉素和Fe(III)-4'-O-四氢吡喃基阿霉素复合物的情况下,三个蒽环类药物分子中约有一个会发生化学修饰,生成一种高度亲脂性衍生物,即7,8-脱氢-9,10-去乙酰阿霉素。其他分子保持不变,即在阿霉素的情况下是高度亲水性的。这两种物质具有不同的荧光光谱,可使用显微分光荧光测定法在细胞内进行鉴定。在Fe(III)-阿霉素复合物的情况下,亲脂性衍生物比亲水性衍生物更迅速地被细胞内化。扩散进入质膜是细胞摄取蒽环类药物的限速步骤;这意味着质膜会加速Fe(III)-蒽环类药物复合物的解离。